Iqvia (IQV) vs. Blueprint Medicines (BPMC) Head-To-Head Analysis

Iqvia (NYSE: IQV) and Blueprint Medicines (NASDAQ:BPMC) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.


This table compares Iqvia and Blueprint Medicines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iqvia 0.58% 12.60% 4.65%
Blueprint Medicines -437.83% -43.11% -34.38%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Iqvia and Blueprint Medicines, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iqvia 0 6 9 0 2.60
Blueprint Medicines 0 0 10 0 3.00

Iqvia currently has a consensus target price of $109.56, indicating a potential upside of 4.66%. Blueprint Medicines has a consensus target price of $83.78, indicating a potential upside of 1.02%. Given Iqvia’s higher possible upside, equities analysts clearly believe Iqvia is more favorable than Blueprint Medicines.

Earnings & Valuation

This table compares Iqvia and Blueprint Medicines’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Iqvia $6.88 billion 3.17 $115.00 million $0.29 360.98
Blueprint Medicines $27.77 million 128.05 -$72.49 million ($3.41) -24.32

Iqvia has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Iqvia, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Iqvia has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Insider & Institutional Ownership

95.9% of Iqvia shares are held by institutional investors. Comparatively, 83.8% of Blueprint Medicines shares are held by institutional investors. 6.4% of Iqvia shares are held by insiders. Comparatively, 3.4% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Iqvia beats Blueprint Medicines on 10 of the 14 factors compared between the two stocks.

Iqvia Company Profile

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply